69

CONGRESO NACIONAL

SOCIEDAD ESPAÑOLA DE
FARMACIA HOSPITALARIA

A CORUÑA

17-19 OCT 24

Prehabilitación ¿Qué puede aportar el farmacéutico?

Experiencia en la implantación de la vía RICA

Francisco López Rodríguez –Arias
Cirugía General y Ap. Digestivo
Hospital General de Elche

Cirugía colorrectal

¿Que le supone al paciente?

Atenuar impacto con ERAS

VÍA CLÍNICA
DE RECUPERACIÓN INTENSIFICADA
EN CIRUGÍA DEL ADULTO
RICA

Association Between Use of Enhanced Recovery After Surgery Protocol and Postoperative Complications in Colorectal Surgery

The Postoperative Outcomes Within Enhanced Recovery After Surgery Protocol (POWER) Study

Figure 4. Moderate to Severe Complications by Enhanced Recovery After Surgery (ERAS Items)

Association Between Use of Enhanced Recovery After Surgery Protocol and Postoperative Complications in Colorectal Surgery

The Postoperative Outcomes Within Enhanced Recovery After Surgery Protocol (POWER) Study

Figure 3. Postoperative Outcomes and Enhanced Recovery After Surgery (ERAS) Adherence

Patients With at Least 1	Adherence	Adherence	Adherence	Adherence	Q1 vs Q4 Odds Ratio (95% CI)	Favors Q1	Favors Q4	Q1 vs Q4 P Value	Adherence Linear Fit (P Value)
	>77.3% Q1 (n=521)	>63.6% but <73.7% Q2 (n=521)	>54.5% but <63.6% Q3 (n=521)	<54.5% Q4 (n=521)					
Moderate or severe complication	84 (16.12)	147 (28.21)	163 (31.39)	183 (35.12)	0.34 (0.25-0.46)	■		<.001 ^a	-0.48 (<.001 ^a)
Complication	143 (27.45)	212 (40.69)	247 (47.41)	277 (53.17)	0.33 (0.26-0.43)	■		<.001 ^a	-0.65 (<.001 ^a)
Readmission	34 (6.53)	34 (6.53)	27 (5.18)	21 (4.03)	1.66 (0.95-2.9)	■	■	.10	+0.05 (.08)
Reintervention	35 (6.72)	33 (6.33)	39 (7.49)	34 (6.53)	0.63 (0.36-1.1)	■	■	.13	-0.09 (.03 ^b)
Mortality rate	3 (0.58)	8 (1.54)	13 (0.62)	11 (2.11)	0.27 (0.07-0.97)	■	■	.06	-0.04 (.01 ^b)
Infection (surgical site, superficial)	32 (6.14)	80 (15.36)	83 (15.93)	114 (21.88)	0.23 (0.15-0.35)	■		<.001 ^a	-0.08 (.007 ^b)
Infection (surgical site, deep)	11 (2.11)	24 (4.61)	33 (6.33)	34 (6.53)	0.31 (0.15-0.62)	■		.001 ^a	-0.10 (<.001 ^a)
Infection (surgical site, organ space)	21 (4.03)	31 (5.95)	31 (5.95)	35 (6.72)	0.58 (0.33-1.01)	■		.07	-0.05 (.11)
Infection (uncertain source)	3 (0.58)	5 (0.96)	10 (1.92)	12 (2.30)	0.25 (0.07-0.88)	■		.03 ^a	-0.05 (.002 ^b)

¿QUÉ ES PREHABILITACIÓN?

un elemento más de ERAS...

¿QUÉ BENEFICIOS TIENE?

Atenúa la pérdida de masa muscular

PreQx

PostQx

Toxicidad a Quimioterapia

A window beneath the skin: how computed tomography assessment of body composition can assist in the identification of hidden wasting conditions in oncology that profoundly impact outcomes

L. E. Daly^{1,2†}, C. M. Prado³ and A. M. Ryan^{1,4*}

Cuestión de supervivencia

Muscle loss 6 months after surgery predicts poor survival of patients with non-metastatic colorectal cancer

Liang Zhang^{1,2†}, Junjie Guan^{3†}, Chao Ding^{2†}, Min Feng^{2*}, Longbo Gong^{1*} and Wenxian Guan^{2*}

**10% pérdida
masa
muscular**

Cuestión de supervivencia

Muscle loss 6 months after surgery predicts poor survival of patients with non-metastatic colorectal cancer

Liang Zhang^{1,2†}, Junjie Guan^{3†}, Chao Ding^{2†}, Min Feng^{2*}, Longbo Gong^{1*} and Wenxian Guan^{2*}

**10% pérdida
masa
muscular**

Mejora los resultados postoperatorios

Prehabilitation Before Major Abdominal Surgery: A Systematic Review and Meta-analysis

Michael J. Hughes¹ · Rosie J. Hackney¹ · Peter J. Lamb¹ · Stephen J. Wigmore¹ ·
D. A. Christopher Deans¹ · Richard J. E. Skipworth¹

World J Surg

20 February 2019

Prehabilitación

**OR 0.63 de
Complicaciones
postoperatorias**

JAMA Surgery | Original Investigation

Effect of Multimodal Prehabilitation on Reducing Postoperative Complications and Enhancing Functional Capacity Following Colorectal Cancer Surgery The PREHAB Randomized Clinical Trial

Charlotte Johanna Laura Molenaar, MD; Enrico Maria Minnella, MD, PhD; Miquel Coca-Martinez, MD, MSc; David Wouter Gerard ten Cate, MD; Marta Regis, PhD; Rashami Awasthi, MSc; Graciela Martínez-Palli, MD, PhD; Manuel López-Baamonde, MD; Raquel Sebío-García, MSc, PhD; Carlo Vittorio Feo, MD; Stefanus Johannes van Rooijen, MD, PhD; Jennifer Marijke Janneke Schreinemakers, MD, PhD; Rasmus Dahlin Bojesen, MD, PhD; Ismail Gögenur, MD, PhD; Edwin R. van den Heuvel, MSc, PhD; Francesco Carli, MD, MPhil; Gerrit Dirk Slooter, MD, PhD; for the PREHAB Study Group

Jun 2023

251 pacientes
Complicaciones severas
29,7% vs 17,1% (Grupo Pre)
OR=0,47

Atenúa pérdida de capacidad funcional

Supportive Care in Cancer (2023) 31:673
<https://doi.org/10.1007/s00520-023-08140-4>

RESEARCH

Home-based prehabilitation improves physical conditions measured by ergospirometry and 6MWT in colorectal cancer patients: a randomized controlled pilot study

Daniel Triguero-Cánovas¹ · Francisco López-Rodríguez-Arias¹ · Manuel Gómez-Martínez² · Luis Sánchez-Guillén¹ · Franc Peris-Castelló² · María José Alcaide-Quirós¹ · Pedro Morillas-Blasco² · Antonio Arroyo¹ · Jose Manuel Ramírez³

¿Cómo diseñamos un programa de Prehabilitación?

1. Controlar la adherencia

Randomized clinical trial of prehabilitation in colorectal surgery

F. Carli¹, P. Charlebois², B. Stein², L. Feldman², G. Zavorsky⁵, D. J. Kim^{3,4}, S. Scott^{3,4}
and N. E. Mayo^{3,4}

Departments of ¹Anesthesia and ²Surgery and ³Division of Clinical Epidemiology, McGill University Health Centre, ⁴School of Physical and Occupational Therapy, McGill University, Montreal, Quebec, Canada, and ⁵Department of Pharmacological and Physiological Science, Saint Louis University, Saint Louis, Missouri, USA

Correspondence to: Dr F. Carli, Department of Anesthesia, McGill University Health Centre, 1650 Cedar Avenue, Room D10-144, Montreal, Quebec, Canada H3G 1A4 (e-mail: franco.carli@mcgill.ca)

VS

Adaptar el programa...

Motivació

Difícil

Protocolo de Ejercicio físico domiciliario

< 200 m
< 4 METs

➤ **Ejercicio aeróbico:**
30 min/día (2,5 Km)

200-350 m
4-7 METs

➤ **Ejercicio aeróbico:**
40 min/día (3,5 Km)

>350 m
>7 METs

➤ **Ejercicio aeróbico:**
50 min/día (4,5 Km)

Ejercicios de resistencia: 3 sesiones/semana (20 minutos por sesión)
Ejercicios funcionales y de movilidad adaptados a la condición física del paciente. Incluye ejercicios de fisioterapia respiratoria.

2. Saber que queremos...

SMI (TAC)
Ángulo Fase
IMEa
Eco muscular
Dinamometría
T6M
Inflamación

Nuevo lenguaje!

Proteínas y algo más...

OPEN ACCESS

BMJ

A systematic review, meta-analysis and meta-regression of the effect of protein supplementation on resistance training-induced gains in muscle mass and strength in healthy adults

Robert W Morton,¹ Kevin T Murphy,¹ Sean R McKellar,¹ Brad J Schoenfeld,² Menno Henselmans,³ Eric Helms,⁴ Alan A Aragon,⁵ Michaela C Devries,⁶ Laura Banfield,⁷ James W Krieger,⁸ Stuart M Phillips¹

2. Control lista de espera

Journal of Cancer Research and Clinical Oncology (2022) 148:2187–2213
<https://doi.org/10.1007/s00432-022-04088-w>

REVIEW – CANCER RESEARCH

Effects and duration of exercise-based prehabilitation in surgical therapy of colon and rectal cancer: a systematic review and meta-analysis

Roberto Falz¹ · Christian Bischoff¹ · René Thieme² · Johannes Lässig¹ · Matthias Mehdorn² · Sigmar Stelzner² · Martin Busse¹ · Ines Gockel²

Received: 24 March 2022 / Accepted: 23 May 2022 / Published online: 13 June 2022
© The Author(s) 2022

<3 semanas

≥3 semanas

T6M 13 m
OR 1.6 (0.76-2.67)

T6M 33 m
OR 0.66 (0.4 - 1.1)

4. Continuidad...

Diagnóstico

Oncólogo

Quirófano

Equipo Multidisciplinar

Cirujanos

Anestesiastas

Fisioterapeutas

Nutricionistas

Psicólogos

Enfermería

A. Primaria

Prehabilitación

Farmacéuticos

INFORME MORFOFUNCIONAL

Número:
Apellidos:
Sexo: Varón
Edad: 70 años **Altura:** 1.70 m **Peso:** 65 kg

Pruebas funcionales
Tasa de los 6 minutos: 280 metros
Dinamometría: 20 mm de Hg

Bio-impedanciometría
Ángulo de fase: -5.4
ASM: 6 kg/m³

Toma de decisiones

Farmacéuticos

Información

69 CONGRESO NACIONAL
SOCIEDAD ESPAÑOLA DE FARMACIA HOSPITALARIA
A CORUÑA 17-19 OCT 24

A CORUÑA
17-19 OCT 24

Gracias por su atención

Franloarias@hotmail.com

@coloproctoelche

69

**CONGRESO
NACIONAL**

SOCIEDAD ESPAÑOLA DE
FARMACIA HOSPITALARIA